<DOC>
	<DOCNO>NCT01847638</DOCNO>
	<brief_summary>To investigate inflammation , visual acuity macular thickness treatment Prolensa v Ilevro cataract surgery .</brief_summary>
	<brief_title>Prolensa ( Bromfenac ) 0.07 % QD vs. Ilevro ( Nepafenac ) 0.3 % QD Treatment Ocular Inflammation Post Cataract Surgery</brief_title>
	<detailed_description>To investigate clinical outcome inflammation , visual acuity macular thickness treatment Prolensa ( bromfenac ophthalmic solution ) 0.07 % QD subject undergone cataract extraction posterior chamber intraocular lens implantation .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Papilledema</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Bromfenac</mesh_term>
	<mesh_term>Nepafenac</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Are male female least 18 year age require cataract surgery surgical procedure cataract surgery . Agree ocular surgical procedure study fellow ( non study ) eye within 15 day prior initiation dose test article throughout duration study . Have Best Corrected Visual Acuity 20/200 good either eye . Are able self administer test article ( caregiver available instill dose test article ) . Have know hypersensitivity bromfenac , nepafenac , loteprednol component test article ( include `` procedural '' medication anesthetic and/or fluorescein drop , dilate drop , etc. ) . Have know hypersensitivity salicylate ( i.e. , aspirin ) NSAIDs ( nonsteroidal antiinflammatory drug ) . Have intraocular inflammation ( i.e. , cell flare anterior chamber measure slit lamp examination ) study eye screen visit . Have know blood dyscrasia bone marrow suppression , diagnosis uncontrolled/unstable peptic ulcer disease , inflammatory bowel disease , ulcerative colitis , uncontrolled/unstable pulmonary , cardiac , vascular , autoimmune , hepatic , renal , central nervous system disease . Have use ocular , topical , systemic NSAIDs ocular , topical , systemic gentamicin , cyclosporine ophthalmic emulsion within 7 day prior initiation dose test article throughout duration study , exception allow patient stable dose aspirin 81 mg daily less . Have use ocular prostaglandin within 30 day prior initiation dose test article throughout duration study . Have active corneal pathology note study eye screen visit . Active corneal pathology define corneal pathology non stable , great mild , compromise assessment safety efficacy treatment . Superficial punctate keratitis study eye . Have extraocular/intraocular inflammation study eye screen visit ( blepharitis allow mild , concurrent conjunctivitis lid erythema/edema ) ongoing , unresolved uveitis . Have use topical , ocular , inhaled systemic steroid within 14 day prior screen . Have radial keratotomy , corneal transplant , corneal refractive surgery study eye within last two year . Have history abuse alcohol/drugs within six month prior screen visit . Are pregnant nursing/lactating . Have participate study investigational drug device within 30 day prior randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Retinal edema</keyword>
	<keyword>Cataract</keyword>
	<keyword>inflammation</keyword>
</DOC>